Core Insights - Bavarian Nordic A/S has secured a contract valued over DKK 200 million to supply its MVA-BN smallpox/mpox vaccine to a European country, enhancing national preparedness against biological threats [1][2] - The total value of secured contracts in the Public Preparedness business has now exceeded DKK 3,000 million, aligning with the company's targeted guidance for 2025 [2][5] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in multiple countries, originally developed for smallpox vaccination [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, particularly in the area of mpox and smallpox [4] - The company aims to enhance public health preparedness and has a strong portfolio of travel vaccines [4] Financial Performance - The company maintains its revenue guidance for 2025 at DKK 5,700-6,700 million, with an EBITDA margin projected between 26-30% [2]